PORTLAND, Ore., June 25 /PRNewswire/ -- Catalyst Financial Resources, LLC has initiated coverage on Rexahn Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs.
The full report is available on the Catalyst website: http://www.catalystresearch.com
In the report, the analyst writes that Rexahn Pharmaceuticals has been developing innovative next-stage treatments that reduce toxicity. Rexahn has drug candidates in clinical development for cancer, CNS-related disorders including social phobia and sexual dysfunction. In 2007, three Phase II trials are planned to be conducted, and one Phase I study is planned to start in 2008. Archexin, Rexahn's lead oncology candidate, is in its Phase II, which will measure the anti-tumor activity of Archexin in patients with advanced renal cell carcinoma (RCC), and is expected to take two years.
About Catalyst Financial Resources, LLC
Catalyst Financial Resources, LLC is an investor awareness firm helping small- and micro-cap companies gain credible exposure in the financial community. Employing the Catalyst System, we augment a firm's existing investor relations activities and assist in achieving appropriate valuation in the marketplace. The Catalyst System was born out of an intense commitment to the small-cap, under-followed market and the need to forge a new standard on Wall Street. Founded in 2002 by Marc Robins, CFA, Catalyst Financial Resources has a proven track record of meeting the needs of both the management and the shareholders of small-cap companies.
Catalyst Financial Resources, LLCCONTACT: Connie Schadewitz of Catalyst Financial Resources, LLC,+1-360-828-8601
Web site: http://www.catalystresearch.com/
